SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Psylo, a leader in neurotherapeutics discovery and development, has officially rebranded as Xylo Bio. This transformation reflects the company's growth, ...

A review of the FDA’s drug approvals of 2024 shows that small companies loomed large—both in the sheer number of nods g | ...

A middle school student in Chicago made headlines by uncovering a remarkable medical breakthrough hidden in a surprising ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Dr. Buchanan will helm Belharra's research organization as the company progresses its lead immunology and oncology programs, advances activities with its pharma collaborators, and enriches its ...

Additionally, rapid, substantial and sustained statistically significant reductions in 17-OHP, a confirmatory secondary biomarker of disease control, were achieved across doses. Treatment with ...

Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone ...

Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk ...

An international research team has discovered a new type of skeletal tissue that offers great potential for advancing regenerative medicine and tissue engineering.

Cancer metastasis -- the spread of cancer to other organs -- is the leading cause of death among cancer patients. Researchers have now uncovered a 'genetic signature' of 177 genes shared across ...